Ipamorelin safety, acetate and legal questions
Some answers are firm. Others need a distinction before they can be answered at all.
Is Ipamorelin FDA approved?
No. Ipamorelin has no approved medical indication. Its published Phase 2 bowel-surgery trial missed the primary endpoint. A clinician’s prescribing decision, a compounding review and drug approval are separate matters; the approval record gives each its own space.
Is Ipamorelin illegal?
Ipamorelin is not a controlled substance. That fact does not, by itself, establish that a particular sale, prescription, compounding operation or possession is lawful. Jurisdiction and the activity matter. I distrust a yes-or-no legal answer that never names either.
The 503A and 503B entry concerns U.S. compounding. Other activities and jurisdictions need their applicable rules. This site does not give an individual legal determination.
Is Ipamorelin acetate a different approved drug?
No. Acetate identifies the salt form. On FDA's page current as of April 22, 2026, ipamorelin acetate remains Category 2 under the 503B interim policy and appears separately among nominated-but-withdrawn substances. FDA supplies no withdrawal date. Withdrawal did not confer approval or compounding clearance.
A brief perioperative safety window
The short intravenous surgery trial and acute blood-level study in healthy men do not establish long-term safety. No ipamorelin-specific safety signal stood out in the brief perioperative window, but that result cannot answer months or years of use. The safety file separates those human findings from mechanism and animal concerns.
Was Ipamorelin discontinued?
There was no approved ipamorelin medicine to withdraw. The published bowel-recovery trial did not establish efficacy, and there is no completed Phase 3 trial or approved indication. A claim that a pharmacy stopped offering something is a different question from withdrawal of an approved drug.
Belly-fat and muscle claims for Ipamorelin
Those benefits have not been established in controlled human trials. Chemotherapy-treated ferrets retained more weight; rat bones grew longer. Neither finding is a human belly-fat or muscle-building result. I give those animal outcomes their actual names rather than a more marketable one.
Ipamorelin hunger reports and the weight question
Extra hunger appears in anecdotal accounts, which are not clinical evidence. The human weight question remains unanswered by the trials here. The ghrelin-receptor action described in the original experiments makes appetite a sensible study question. An individual prediction would need evidence from people.
Are vivid dreams a measured benefit?
No. Deeper sleep, vivid dreams, less soreness and a leaner appearance are reported anecdotally. So are flushing, swelling, tingling, dizziness and irritation at an injection site. These accounts are not clinical evidence and cannot establish which changes ipamorelin caused. Food, exercise and other treatments can complicate the accounts.
Does Ipamorelin increase IGF-1?
The rat study gives a qualified answer. In the 15-day rat bone-growth study, longitudinal bone growth increased without a change in total systemic IGF-1. It documents the response in rats. Individual human blood levels remain another question. Growth-hormone and IGF-1 activity still raises safety questions that short experiments cannot resolve.
CJC-1295 Ipamorelin: benefit and safety still untested
Different mechanisms of growth-hormone release explain the interest in combining them. They do not establish clinical benefit or long-term safety for the pair. Ipamorelin’s single-agent blood study cannot become a combination trial. The research entry gives the rationale its due without supplying a dose or schedule.
Can Ipamorelin be taken orally?
No published human pill test establishes oral absorption and benefit. The healthy-volunteer study and surgery trial used intravenous administration. Neither documents a successful swallowed formulation. The oral ipamorelin page examines that missing result.
Ipamorelin in blood: a roughly 2-hour half-life
After intravenous administration in healthy volunteers, the terminal half-life was approximately 2 hours, with the growth-hormone pulse peaking around 40 minutes. Those timings describe the drug concentration and hormone pulse.
Is Ipamorelin banned by WADA?
Yes, at all times under category S2. A prescription does not lift that sports prohibition. The peptide-doping review discusses detection challenges associated with the short half-life; urine-detection methods exist. The substance can still be detected.
Inside a research-product test report
A report addresses the tests it actually performed. It does not establish treatment benefit or FDA approval. The seized-material analyses found modified analogues, which is a particularly concrete reason to separate a label from chemical identity. Identity alone also cannot establish sterility or long-term safety.